Influence of a Clinical Pharmacist's Intervention on Quality of Life of a Breast Cancer Patient Under Adjuvant Chemotherapy

University Hospital "Sestre Milosrdnice"0 sites70 target enrollmentApril 2016

ConditionsBreast Cancer, Quality of Life

Overview

Phase: N/A
Intervention: Not specified
Conditions: Breast Cancer, Quality of Life
Sponsor: University Hospital "Sestre Milosrdnice"
Enrollment: 70
Primary Endpoint: changes in quality of life of a breast cancer patient under chemotherapy, after a clinical pharmacist's behavioral intervention, measured by EORTC B23 questionnaire
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The purpose of this study is to investigate the impact of pharmacist behavioral intervention's influence on breast cancer patients' quality of life. Croatian randomized controlled trial. Targeted population: general population of breast cancer patients under the first adjuvant anthracycline chemotherapy. Primary outcome: difference in EORTC QLQ-BR23 questionnaire result from the baseline to after 3 week cycle.

Registry

clinicaltrials.gov

Start Date

April 2016

End Date

June 2016

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

University Hospital "Sestre Milosrdnice"

Responsible Party

Principal Investigator

Robert Šeparović

MD PHD

University Hospital "Sestre Milosrdnice"

Eligibility Criteria

Inclusion Criteria

•Early breast cancer
•First adjuvant chemotherapy
•Chemotherapy protocol: anthracycline x 4

Exclusion Criteria

•Cardiovascular comorbidities
•Regular nausea or vomiting during six months before enrollment
•Unable to answer the quality of life questionnaire on their own

Outcomes

Primary Outcomes

changes in quality of life of a breast cancer patient under chemotherapy, after a clinical pharmacist's behavioral intervention, measured by EORTC B23 questionnaire

Time Frame: up to two months